ArticleToxicology reports2024
Protective effect of
Article in Toxicology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative safety signals of carboplatin and cisplatin in lung cancer: a pharmacovigilance study based on FAERS.Frontiers in medicine · 2026Article
- In Vitro and in Vivo Efficacy of Different Ointment Formulations ContainingPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients who are receiving carboplatin therapy for cancer often experience toxic side effects. This study examined the effects of lyophilized aqueous leaf extracts of F. capensis (LALEFC) on oxidative stress and inflammatory markers in albino rats with carboplatin-damaged livers. We randomly assigned 35 rats to five experimental groups. Groups 2-5 underwent liver injury induction using carboplatin, while groups 1 and 2 served as the normal and carboplatin control groups, respectively. Groups 3-5 were the treatment groups. Treatments were performed for 17 days. We analyzed the quantitative phytochemical constituents of LALEFC using standard procedures and analyzed the liver oxidative stress and inflammatory markers using liver homogenate. The phytochemical constituents of LALEFC (mg/100 g) occur in the following order: The most abundant compounds were phenols (1577.72 ± 0.008), flavonoids (1253.13 ± 0.007), tannins (878.97 ± 0.007), alkaloids (652.66 ± 0.007), glycosides (314.39 ± 0.011), and terpenoids (261.18 ± 0.154), while steroids (0.573 ± 0.062), saponins (0.370 ± 0.003), and HCN (0.254.00 ± 0.006) were found in trace amount. The study of oxidative stress and inflammatory markers showed that giving carboplatin to rats greatly increased the levels of interleukin-1 (IL-1), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), nuclear factor-kappa B (NF-α), malondialdehyde (MDA), reactive oxygen species (ROS), and caspase-3 activity. It also decreased the levels of reduced glutathione (GSH) and the activities of glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). D). However, coadministration of LALEFC significantly restored the altered oxidative and inflammatory responses. This finding suggested that carboplatin induced liver injury through redox imbalance, which elevated the expression of inflammatory markers. LALEFC's restoration of altered markers could be relevant in the treatment of carboplatin-induced liver injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.